Updated on 4 September 2012
Stride subsidiaryâs cancer drug Vinorelbine to be launched through Pfizer following US FDA approval
Singapore: Onco Therapies Limited, a wholly-owned subsidiary of
Strides Arcolab, received final abbreviated new drug application (ANDA) approval for Vinorelbine injection 10 mg/mL packaged in 10 mg/1 mL and 50 mg / 5mL single-dose vials.
Vinorelbine is part of Onco Therapies' oncology portfolio that has been licensed to Pfizer for the US market and the product is available for immediate launch.
Vinorelbine is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
